login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PROQR THERAPEUTICS NV (PRQR) Stock News
USA
- NASDAQ:PRQR -
NL0010872495
-
Common Stock
2.95
USD
-0.1 (-3.28%)
Last: 10/21/2025, 8:00:02 PM
2.9
USD
-0.05 (-1.69%)
After Hours:
10/21/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PRQR Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Chartmill
- Mentions:
THM
MSN
SLI
YGMZ
...
Curious about the stocks that are showing activity after the closing bell on Thursday?
2 days ago - By: ProQR Therapeutics N.V.
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
2 days ago - By: ProQR Therapeutics N.V.
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
9 days ago - By: ProQR Therapeutics N.V.
ProQR to Participate in Upcoming Investor Conferences in October 2025
9 days ago - By: ProQR Therapeutics N.V.
ProQR to Participate in Upcoming Investor Conferences in October 2025
a month ago - By: Benzinga
- Mentions:
BLRX
SXTC
CNSP
BCAB
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
3 months ago - By: Zacks Investment Research
- Mentions:
NTLA
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
3 months ago - By: ProQR Therapeutics N.V.
ProQR Announces Second Quarter 2025 Operating and Financial Results
3 months ago - By: ProQR Therapeutics N.V.
ProQR Announces Second Quarter 2025 Operating and Financial Results
3 months ago - By: ProQR Therapeutics N.V.
ProQR Announces Upcoming Presentation at RNA Editing Summit
4 months ago - By: ProQR Therapeutics N.V.
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
4 months ago - By: ProQR Therapeutics N.V.
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
5 months ago - By: ProQR Therapeutics N.V.
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
6 months ago - By: ProQR Therapeutics N.V.
ProQR Announces First Quarter 2025 Operating and Financial Results
6 months ago - By: ProQR Therapeutics N.V.
ProQR Announces First Quarter 2025 Operating and Financial Results
6 months ago - By: ProQR Therapeutics N.V.
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
6 months ago - By: ProQR Therapeutics N.V.
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
6 months ago - By: ProQR Therapeutics N.V.
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
6 months ago - By: Yahoo Finance
- Mentions:
BBIO
TVGN
ATRC
REGN
...
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald
6 months ago - By: Yahoo Finance
ProQR Therapeutics initiated with an Outperform at Evercore ISI
6 months ago - By: ProQR Therapeutics N.V.
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
6 months ago - By: ProQR Therapeutics N.V.
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
7 months ago - By: ProQR Therapeutics N.V.
ProQR Announces Year End 2024 Operating and Financial Results
7 months ago - By: ProQR Therapeutics N.V.
ProQR Announces Year End 2024 Operating and Financial Results
8 months ago - By: Benzinga
- Mentions:
CART
RL
VFC
BZAI
This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
10 months ago - By: ProQR Therapeutics N.V.
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
11 months ago - By: ProQR Therapeutics N.V.
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
11 months ago - By: ProQR Therapeutics N.V.
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
a year ago - By: ProQR Therapeutics N.V.
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
a year ago - By: ProQR Therapeutics N.V.
ProQR Announces Third Quarter 2024 Operating and Financial Results
a year ago - By: ProQR Therapeutics N.V.
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
a year ago - By: ProQR Therapeutics N.V.
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
a year ago - By: ProQR Therapeutics N.V.
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
a year ago - By: ProQR Therapeutics N.V.
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
a year ago - By: ProQR Therapeutics N.V.
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
a year ago - By: ProQR Therapeutics N.V.
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
Please enable JavaScript to continue using this application.